Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 21;3(11):1351–1366. doi: 10.1038/s43018-022-00456-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a, Mouse colon cancer MC38 cells were engrafted into both flanks of C57Bl/6 immunocompetent syngeneic mice and only right-sided tumors were irradiated. b, Growth curves of MC38 allografts with the indicated treatments in irradiated and non-irradiated tumors. n = 1 experiment with n = 6 (control, anti-CD47 and RT) or n = 7 (RT + anti-CD47) mice. Irradiated tumors, ***P = 0.0006, ***P = 0.0006; non-irradiated tumors, **P = 0.0015, ***P = 0.0002. c, As in a with MC38 allografts in C57BL/6 mice except that CD8⁺ T cells were depleted with anti-CD8 antibody treatment. n = 1 experiment with n = 7 mice except RT + anti-CD47 (n = 8 mice). Irradiated tumors (control), ***P = 0.0002, ***P = 0.0002; irradiated tumors (CD8-depleted), ***P = 0.0006, ***P = 0.0006; non-irradiated tumors (control), ***P = 0.0003, ***P = 0.0003; non-irradiated tumors (CD8-depleted), ****P < 0.0001. d, Quantification of tumor-infiltrating CD8⁺ T cells in non-irradiated tumors from f. n = 1 experiment with n = 7 mice except RT + anti-CD47 (n = 8 mice). e, Growth curves of MC38 allografts with the indicated treatments in irradiated and non-irradiated tumors. n = 1 experiment with n = 7 (RT + anti-CD47) or n = 8 (RT + anti-CD47 + anti-PD-1) mice (two tumors per mouse). ****P < 0.0001. f, Quantification of tumor-infiltrating macrophages, M2-like macrophages, total T cells, CD4⁺ T cells and CD8⁺ T cells in non-irradiated tumors from e by flow cytometry. n = 1 experiment with n = 7 (RT + anti-CD47) or 8 (RT + anti-CD47 + anti-PD-1) mice. ***P = 0.0003, ***P = 0.0006, **P = 0.0078. Two-tailed Student’s t-tests following two-way ANOVA were performed in b (irradiated tumors, P < 0.0001; non-irradiated tumors, P < 0.0001), c (irradiated tumors, P < 0.0001; non-irradiated tumors, P < 0.0001) and e (irradiated tumors, P = 0.7841; non-irradiated tumors, P < 0.0001). Two-tailed Student’s t-tests following one-way ANOVA were performed in d (control, P = 0.0908; CD8-depleted, P = 0.4161). Two-tailed Student’s t-tests were performed for f. Error bars represent s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Source data